All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Theradex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021
Details:
The trial is an open label, exploratory phase I/II trial adding ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first and second (and later) line MPM to assess safety, immune activation and clinical efficacy vs SoC only.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: ICON Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
An 18-month analysis shows that median Overall Survival (mOS) will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14.2 months or less in the chemotherapy-only control group.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 177Lu lilotomab satetraxetan,Rituximab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Data from this cohort is expected in H1'2021 and will be analysed alongside the data generated from the first cohort of patients receiving 10 MBq/kg Betalutin®/40mg lilotomab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UV1,GM-CSF
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. The publication will cover detailed outcomes of the study for the 18 patients receiving UV1 monotherapy as maintenance treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UV1,GM-CSF
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Ultimovacs has established a growing body of clinical data demonstrating a strong safety and tolerability profile for UV1 and a range of preliminary efficacy signals in several cancer indications, all of which supports the further development the product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ONCOS-102,Durvalumab
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The study is a phase I/II trial assessing the combination of intra-peritoneally delivered ONCOS-102 in combination with systemically administered durvalumab, in patients with colorectal or platinum-resistant ovarian cancers that have metastasized to the peritoneal cavity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The data presented in this paper are aligned with the preliminary results presented by Dr Kolstad at the American Society of Hematology medical conference in December 2018:Overall response rate (ORR) was 61% and complete response (CR) was 30% for all 74 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bemcentinib
Therapeutic Area: Oncology Product Name: BGB 324
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Alabama
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
This is an open label, multi-centre, intra-tumoral tissue pharmacokinetic (PK) study of bemcentinib in patients with recurrent glioblastoma for whom a surgical resection is medically indicated.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
